Cognition Therapeutics Presents Poster Of Participant Demographics From Phase 2 Dementia With Lewy Bodies Study At CTAD
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics presented participant demographics from its Phase 2 'SHIMMER' study on dementia with Lewy bodies at the CTAD conference. The study's patient characteristics align with other DLB studies.
October 31, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cognition Therapeutics presented participant demographics from its Phase 2 'SHIMMER' study on dementia with Lewy bodies at the CTAD conference. The study's patient characteristics align with other DLB studies.
The presentation of participant demographics from the Phase 2 'SHIMMER' study at a major conference like CTAD is a positive development for Cognition Therapeutics. It indicates progress in their clinical trials, which could boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90